Literature DB >> 8617199

Delineation of the peptide binding site of the human galanin receptor.

K Kask1, M Berthold, U Kahl, G Nordvall, T Bartfai.   

Abstract

Galanin, a neuroendocrine peptide of 29 amino acids, binds to Gi/Go-coupled receptors to trigger cellular responses. To determine which amino acids of the recently cloned seven-transmembrane domain-type human galanin receptor are involved in the high-affinity binding of the endogenous peptide ligand, we performed a mutagenesis study. Mutation of the His264 or His267 of transmembrane domain VI to alanine, or of Phe282 of transmembrane domain VII to glycine, results in an apparent loss of galanin binding. The substitution of Glu271 to serine in the extracellular loop III of the receptor causes a 12-fold loss in affinity for galanin. We combined the mutagenesis results with data on the pharmacophores (Trp2, Tyr9) of galanin and with molecular modelling of the receptor using bacteriorhodopsin as a model. Based on these studies, we propose a binding site model for the endogenous peptide ligand in the galanin receptor where the N-terminus of galanin hydrogen bonds with Glu271 of the receptor, Trp2 of galanin interacts with the Zn2+ sensitive pair of His264 and His267 of transmembrane domain VI, and Tyr9 of galanin interacts with Phe282 of transmembrane domain VII, while the C-terminus of galanin is pointing towards the N-terminus of th

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617199      PMCID: PMC449938     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  35 in total

1.  Galanin receptors in human hypothalamus: biochemical and structural analysis.

Authors:  A M Lorinet; F Javoy-Agid; M Laburthe; B Amiranoff
Journal:  Eur J Pharmacol       Date:  1994-09-15       Impact factor: 4.432

2.  A hot spot of binding energy in a hormone-receptor interface.

Authors:  T Clackson; J A Wells
Journal:  Science       Date:  1995-01-20       Impact factor: 47.728

3.  Molecular cloning of a functional human galanin receptor.

Authors:  E Habert-Ortoli; B Amiranoff; I Loquet; M Laburthe; J F Mayaux
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

4.  Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy.

Authors:  V M Unger; G F Schertler
Journal:  Biophys J       Date:  1995-05       Impact factor: 4.033

5.  Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor.

Authors:  H T Schambye; S A Hjorth; J Weinstock; T W Schwartz
Journal:  Mol Pharmacol       Date:  1995-03       Impact factor: 4.436

6.  Differentiation between binding sites for angiotensin II and nonpeptide antagonists on the angiotensin II type 1 receptors.

Authors:  H T Schambye; S A Hjorth; D J Bergsma; G Sathe; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Human endothelin receptor ETB. Amino acid sequence requirements for super stable complex formation with its ligand.

Authors:  T Takasuka; T Sakurai; K Goto; Y Furuichi; T Watanabe
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

8.  Conversion of antagonist-binding site to metal-ion site in the tachykinin NK-1 receptor.

Authors:  C E Elling; S M Nielsen; T W Schwartz
Journal:  Nature       Date:  1995-03-02       Impact factor: 49.962

9.  Galantide stimulates sexual behaviour in male rats.

Authors:  A Benelli; R Arletti; A Bertolini; B Menozzi; R Basaglia; R Poggioli
Journal:  Eur J Pharmacol       Date:  1994-08-01       Impact factor: 4.432

10.  Two amino acids, located in transmembrane domains VI and VII, determine the selectivity of the peptide agonist SMS 201-995 for the SSTR2 somatostatin receptor.

Authors:  K Kaupmann; C Bruns; F Raulf; H P Weber; H Mattes; H Lübbert
Journal:  EMBO J       Date:  1995-02-15       Impact factor: 11.598

View more
  9 in total

Review 1.  Modes of peptide binding in G protein-coupled receptors.

Authors:  M Berthold; T Bartfai
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

Review 2.  Understanding Peptide Binding in Class A G Protein-Coupled Receptors.

Authors:  Irina G Tikhonova; Veronique Gigoux; Daniel Fourmy
Journal:  Mol Pharmacol       Date:  2019-07-10       Impact factor: 4.436

Review 3.  Positive allosteric modulators to peptide GPCRs: a promising class of drugs.

Authors:  Tamas Bartfai; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

4.  Specific binding of proinsulin C-peptide to human cell membranes.

Authors:  R Rigler; A Pramanik; P Jonasson; G Kratz; O T Jansson; P Nygren; S Stâhl; K Ekberg; B Johansson; S Uhlén; M Uhlén; H Jörnvall; J Wahren
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

5.  GPCR-I-TASSER: A Hybrid Approach to G Protein-Coupled Receptor Structure Modeling and the Application to the Human Genome.

Authors:  Jian Zhang; Jianyi Yang; Richard Jang; Yang Zhang
Journal:  Structure       Date:  2015-07-16       Impact factor: 5.006

6.  Structural insights into galanin receptor signaling.

Authors:  Wentong Jiang; Sanduo Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-20       Impact factor: 12.779

7.  Unravelling the Evolution of the Allatostatin-Type A, KISS and Galanin Peptide-Receptor Gene Families in Bilaterians: Insights from Anopheles Mosquitoes.

Authors:  Rute C Felix; Marlene Trindade; Isa R P Pires; Vera G Fonseca; Rute S Martins; Henrique Silveira; Deborah M Power; João C R Cardoso
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

Review 8.  Pathogenicity-associated protein domains: The fiercely-conserved evolutionary signatures.

Authors:  Seema Patel
Journal:  Gene Rep       Date:  2017-04-08

9.  Modelling the structures of G protein-coupled receptors aided by three-dimensional validation.

Authors:  Siavoush Dastmalchi; W Bret Church; Michael B Morris
Journal:  BMC Bioinformatics       Date:  2008       Impact factor: 3.169

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.